Leerink Partnrs Predicts Increased Earnings for Scholar Rock

Key Points

• Leerink Partnrs has raised its earnings per share (EPS) estimates for Scholar Rock, predicting a loss of ($0.95) for Q3 2025, an improvement from the previous estimate of ($0.99).
• The stock has a consensus rating of "Buy" with a consensus price target of $46.40, while ten analysts have assigned a Buy rating and three a strong buy rating to the stock.
• Scholar Rock reported ($0.98) EPS in its last quarterly results, missing consensus estimates, and has current full-year earnings expectations of ($2.42) per share.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) - Stock analysts at Leerink Partnrs raised their Q3 2025 EPS estimates for shares of Scholar Rock in a research report issued to clients and investors on Tuesday, September 23rd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($0.95) for the quarter, up from their previous forecast of ($0.99). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Scholar Rock's Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($3.44) EPS, FY2026 earnings at ($2.34) EPS, FY2027 earnings at ($2.71) EPS and FY2028 earnings at ($1.44) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.32). During the same period last year, the company earned ($0.60) EPS.

A number of other brokerages also recently weighed in on SRRK. Cantor Fitzgerald began coverage on shares of Scholar Rock in a research report on Thursday, July 17th. They set an "overweight" rating on the stock. Jefferies Financial Group initiated coverage on shares of Scholar Rock in a report on Thursday, August 21st. They issued a "buy" rating and a $50.00 target price for the company. Raymond James Financial set a $53.00 price objective on shares of Scholar Rock and gave the company a "strong-buy" rating in a report on Wednesday, July 30th. Wedbush reiterated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, June 18th. Finally, Piper Sandler reduced their price target on shares of Scholar Rock from $52.00 to $51.00 and set an "overweight" rating for the company in a report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the stock. According to MarketBeat.com, Scholar Rock has a consensus rating of "Buy" and a consensus price target of $46.40.

Scholar Rock Stock Performance

Scholar Rock stock opened at $34.49 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.33 and a current ratio of 6.33. Scholar Rock has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The stock has a market cap of $3.32 billion, a price-to-earnings ratio of -11.85 and a beta of 0.36. The stock's 50 day simple moving average is $34.16 and its two-hundred day simple moving average is $33.05.

Institutional Investors Weigh In On Scholar Rock

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SRRK. Vanguard Group Inc. grew its stake in shares of Scholar Rock by 2.1% in the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company's stock valued at $155,773,000 after buying an additional 101,723 shares in the last quarter. Bellevue Group AG lifted its stake in Scholar Rock by 17.6% during the second quarter. Bellevue Group AG now owns 2,947,295 shares of the company's stock worth $104,393,000 after purchasing an additional 440,405 shares during the last quarter. Eventide Asset Management LLC lifted its stake in Scholar Rock by 9.5% during the second quarter. Eventide Asset Management LLC now owns 2,913,246 shares of the company's stock worth $103,192,000 after purchasing an additional 251,638 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Scholar Rock by 26.5% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,018,000 shares of the company's stock worth $64,879,000 after purchasing an additional 423,131 shares during the last quarter. Finally, Hood River Capital Management LLC lifted its stake in Scholar Rock by 1.6% during the second quarter. Hood River Capital Management LLC now owns 1,974,964 shares of the company's stock worth $69,953,000 after purchasing an additional 30,806 shares during the last quarter. Hedge funds and other institutional investors own 91.08% of the company's stock.

Insider Activity

In other news, Director Katie Peng sold 1,006 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $32.53, for a total value of $32,725.18. Following the transaction, the director owned 33,914 shares in the company, valued at $1,103,222.42. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mo Qatanani sold 24,066 shares of the firm's stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $34.44, for a total value of $828,833.04. Following the completion of the transaction, the insider owned 115,495 shares in the company, valued at approximately $3,977,647.80. This trade represents a 17.24% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 42,739 shares of company stock worth $1,516,584 over the last quarter. 13.30% of the stock is currently owned by corporate insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.